Investment firm OrbiMed closed its second healthcare royalty and credit opportunities Fund, at $924m.
Investors in OrbiMed Royalty Opportunities II, LP, include a broad range of premier endowment, foundation, pension and other institutional investors. It also included $24m from the General Partner.
The new fund will acquire healthcare royalty streams and provide tailored debt capital solutions to healthcare companies and institutions worldwide. The Fund expects to commit between $20m to $150m per investment, with the ability to commit larger amounts in collaboration with other OrbiMed funds.
Led by Samuel D. Isaly, Managing Partner, W. Carter Neild, Partner, Tadd Wessel and Matthew Rizzo, Managing Directors, OrbiMed is an investment firm dedicated exclusively to the healthcare sector, with over $14 billion in assets under management. It invests globally across the spectrum of healthcare companies, from venture capital start-ups to large multinational companies utilizing a range of private equity funds, public equity funds, royalty/debt funds and other investment vehicles.
OrbiMed maintains its headquarters in New York City, with additional offices in San Francisco, Shanghai, Mumbai and Herzliya.